Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fibrinogen + thrombin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Fibrocaps (brand name Raplixa) is a dry powder fibrin sealant consisting of human plasma-derived fibrinogen and thrombin. It is used as an adjunct to hemostasis during surgical procedures to control mild to moderate bleeding when conventional techniques are insufficient. The product is unique for its dry powder formulation, which is stable at room temperature and can be applied directly to the bleeding site or via a gelatin sponge. It was developed by ProFibrix and later acquired by Mallinckrodt Pharmaceuticals.
- Brand names
- RaplixaFibrocaps
- Other names
- Dry powder fibrin sealant
02
Targets
Fibrin (Factor Ia)F2 (Thrombin)
Beyond the preview
Go deeper on fibrinogen + thrombin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fibrinogen + thrombin.